Can evidence drive the development of a sound national EPO reimbursement policy?
Wish
Jay B
JB
D000740:Anemia / Q000188:drug therapy / Q000191:economics / Q000453:epidemiology / Q000209:etiology; D014487:Centers for Medicare and Medicaid Services, U.S.; D004921:Erythropoietin / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D019317:Evidence-Based Medicine / Q000639:trends*; D006291:Health Policy; D006801:Humans; D007676:Kidney Failure, Chronic / Q000191:economics; D006278:Medicare / Q000639:trends; D017410:Practice Guidelines as Topic / Q000592:standards; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D020444:Reimbursement, Disproportionate Share / Q000639:trends; D014481:United States
D011994:Recombinant Proteins; D004921:Erythropoietin